Drugs / Sibrotuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02209727 | Dec 2000 → Jun 2002 | non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sibrotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02209727 ↗ |
| Known as | 131I-Sibrotuzumab | “Drug: 131I-Sibrotuzumab” NCT02209727 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108882 ↗ |
| Target | FAP | “Fibroblast activation protein alpha binding agent” CHEMBL2108882 ↗ |